Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product

[Business Wire] – Bristol-Myers Squibb Company today announced that it received the Prix Galien USA 2015 Award for Best Biotechnology Product for Opdivo , the Company’s PD-1 immune checkpoint inhibitor. Read more on . . . → Read More: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product Similar Articles: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – CORRECTING and REPLACING Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27 Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients